<p>The digital health startup says it secured the fresh capital to update its valuation and finance acquisitions.</p>

<p>Beleaguered genetic testing company 23andMe announced Friday that it has reached an agreement to sell itself to TTAM Research Institute, a nonprofit led by the company&#8217;s co-founder and former CEO Anne Wojcicki.</p>

<p>More than two dozen states have sued 23andMe to block the sale of genetic data without customers&#8217; permission.</p>

<p>Since its founding in 2014, a16z Bio+ Health has raised four funds of nearly $3 billion each, including a $1.5 billion fund that closed in 2022.</p>

<p>Omada Health popped in its first day as a public company, validation for founder CEO Sean Duffy.</p>

<p>The company is working on a bio-acoustic project, which will map out the different types of dire wolf howls. </p>

<p>Elon Musk&#8217;s brain computer interface startup Neuralink closed a $650 million funding round, the company announced in a blog post on Monday. The Series E fundraise included investors such as ARK Invest, Founders Fund, Sequoia Capital, and Thrive Capital, among others. Neuralink last raised a $280 million Series D funding round in 2023, with an [&hellip;]</p>

<p>Hinge Health, a digital physical therapy company, closed its first day of trading on the New York Stock Exchange on Thursday at $37.56, up about 17% over the $32 IPO price it set the previous day. That’s a good first-day result. But even with the pop, Hinge’s public valuation is significantly less than its last [&hellip;]</p>

<p>The Series B was led by General Catalyst, with Andreessen Horowitz, Regents of the University of California, Google Ventures, and Accel also investing.</p>

<p>Fieldstone Bio recently raised $5 million in seed funding.</p>

<p>Nine years ago, AI pioneer Geoffrey Hinton sent shock waves through medicine by declaring it &#8220;just completely obvious&#8221; that AI would make radiologists extinct in short order. Fast-forward and the specialists &#8212; who do more than analyze images &#8212; are thriving, observes The New York Times. In fact, the field is experiencing explosive growth amid [&hellip;]</p>

<p>23andMe, the genetic testing giant once valued in the billions, is now navigating Chapter 11 bankruptcy and notifying millions of current and former customers that they may be eligible to file claims as part of the restructuring process. The company and 11 of its subsidiaries, including Lemonaid Health and LPRXOne, filed for bankruptcy protection on [&hellip;]</p>

<p>Whoop has backed down, somewhat, from the controversial upgrade plans around its Whoop 5.0 fitness tracker. When the company first announced Whoop 5.0 this week, it said members who wanted the new device could either extend their subscriptions by 12 months or pay a one-time upgrade fee of $49 ($79 for the model with EKG [&hellip;]</p>

<p>Billy Evans, partner of Theranos founder Elizabeth Holmes, is working on a new startup that seeks to deliver “human health optimization” through blood testing, according to The New York Times. The Times reportedly spoke to two investors pitched on the startup, called Haemanthus, and also viewed some of Haemanthus’ marketing materials. In those materials, the [&hellip;]</p>

<p>For the first time, the FDA has just approved a device that lets people screen for cervical cancer from home. Known as the Teal Wand, from the company Teal Health, the prescription device lets patients self-collect samples and mail them to a lab to receive the same testing as would be done at a doctor’s [&hellip;]</p>

<p>Hims &amp; Hers, the telehealth and wellness company, has hired a veteran of the autonomous vehicle industry as its next chief technology officer. The move, according to Hims &amp; Hers co-founder and CEO Andrew Dudum, was intentional. Hims &amp; Hers on Thursday said its next CTO would be Mo Elshenawy, the former president and CTO [&hellip;]</p>

<p>OpenAI has met with officials from the U.S. Food and Drug Administration (FDA) to discuss the agency&#8217;s use of AI to speed up drug evaluations, Wired reported on Wednesday. According to the report, OpenAI and the FDA have discussed a project called cderGPT, which seems to be an AI tool for the Center for Drug [&hellip;]</p>

<p>FutureHouse, an Eric Schmidt-backed nonprofit that aims to build an &#8220;AI scientist&#8221; within the next decade,&nbsp;has released a new tool that it claims can help support &#8220;data-driven discovery&#8221; in biology. The new tool comes just a week after FutureHouse launched its API and platform. The tool, called Finch, takes in biology data (primarily in the [&hellip;]</p>

<p>With long waiting lists and rising costs in overburdened healthcare systems, many people are turning to AI-powered chatbots like ChatGPT for medical self-diagnosis. About one in six American adults already use chatbots for health advice at least monthly, according to one recent survey. But placing too much trust in chatbots&#8217; outputs can be risky, in [&hellip;]</p>

<p>Blink and you’ll miss it: A startup out of Finland is taking a new look at the market for prescription eyewear. Tapping into innovations in eye-tracking and liquid crystal lens technology, IXI is building low-power glasses that will invisibly and automatically adjust to account for a wearer&#8217;s presbyopia (far-sightedness). Four years into its life, Helsinki-based [&hellip;]</p>